Biosight Completes Enrollment in Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy
Encouraging data support single-agent efficacy across key measures including complete remission (CR) with negative minimal residual disease (MRD) rates, duration...